Genencor
US biotech company
From Wikipedia, the free encyclopedia
Genencor is a biotechnology company based in Palo Alto, CA and a subsidiary of IFF.[1] Genencor is a producer of Industrial enzymes and low-priced bulk protein. It is considered to have pioneered the field of industrial biotechnology, as distinct from traditional applications of biotechnology to health care and agriculture.[2]
![]() | |
| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 1982 |
| Headquarters | Palo Alto, California, U.S. |
Key people | Tjerk de Ruiter (Chairman & CEO) |
| Products | Purafect, Properase, Spezyme |
| Revenue | |
Number of employees | 1,500 (2005) |
| Parent | IFF |
| Website | biosciences |
The name Genencor originates with Genencor, Inc., the original joint venture between Genentech and Corning Incorporated, which was founded in 1982. A.E. Staley made a substantial investment to the company in 1984, making it a partner with Corning and Genentech. After Eastman bought A.E. Staley's share, Genencor became part of Eastman Kodak.[3]
In 2005 Genencor was acquired by Danisco.[4]
In 2008 Genencor entered a joint venture with DuPont, called DuPont Danisco Cellulosic Ethanol LLC, to develop and commercialize low cost technology for the production of cellulosic ethanol.[5] In 2008, Genencor and Goodyear announced they were working to develop BioIsoprene.
In 2011, DuPont acquired Danisco for $6.3 billion.[6]
In 2021, portions of DuPont including the Genencor division were acquired by International Flavors & Fragrances.[7]
Awards
Genencor achieved the following awards:[citation needed]
- Named No. 2 Best Medium-Sized Company to Work for in America by the Great Place to Work® Institute, Inc. (2004)
- Named No. 1 Best Medium-Sized Company to Work for in America by the Great Place to Work® Institute, Inc. (2005)
- Named No. 1 Best Place to Work in the Bay Area by the San Francisco Chronicle (2005)
- Named No. 11 Best Medium-Sized Company to Work for in America by the Great Place to Work® Institute, Inc. (2011)
